CLBIO — Corline Biomedical AB Income Statement
0.000.00%
Last trade - 00:00- SEK199.86m
- SEK182.20m
- SEK9.78m
Annual income statement for Corline Biomedical AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | SAS | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.7 | 7.06 | 23.6 | 25 | 9.78 |
| Cost of Revenue | |||||
| Gross Profit | 10.3 | 9.1 | 22.7 | 28.4 | 13.4 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 11 | 14 | 21.2 | 26.8 | 32.9 |
| Operating Profit | -7.29 | -6.91 | 2.33 | -1.79 | -23.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -7.29 | -6.92 | 2.33 | -1.81 | -23.2 |
| Net Income After Taxes | -7.29 | -6.92 | 2.33 | -1.81 | -23.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.29 | -6.92 | 2.33 | -1.81 | -23.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.29 | -6.92 | 2.33 | -1.81 | -23.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.425 | -0.339 | 0.108 | -0.084 | -0.605 |
| Dividends per Share |